Missense KRAS mutations are present in 40%–45% of the CRC patients and WNT/beta-catenin activity is deregulated via mutations in more than 80% of CRC patients [17,18,19,20,21,22]; therefore, findings from our studies may impact the therapeutic options for a considerable number of patients with this malignancy. Here, KRAS is linked to colorectal carcinoma.